Carcinogenicity assessment of the pan-caspase inhibitor, emricasan, in Tg.rasH2 mice

Regulatory Toxicology and Pharmacology

Volumn 72, Issue 2, 2015, Pages 169-178

  Elbekai, R H ^a   Paranjpe, M G ^a   Contreras, P C ^b   Spada, A ^b  

^a BioReliance by SAFC ^*  (United States)

^b Conatus Pharmaceuticals ^*  (United States)

Author keywords

Carcinogenicity; Caspase inhibitor; Emricasan; IDN 6556; Tg.rasH2

Indexed keywords

EMRICASAN; URETHAN; 3-(2-(2-TERT-BUTYLPHENYLAMINOOXALYL)AMINOPROPIONYLAMINO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID; CASPASE INHIBITOR; VALERIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER INCIDENCE; CARCINOGENICITY; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; GERMINAL CENTER; HISTOPATHOLOGY; LEUKOCYTE COUNT; LIVER GRANULOMA; LYMPH NODE; MALE; MANDIBULAR LYMPH NODE; MESENTERY LYMPH NODE; MORTALITY; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; SEX DIFFERENCE; TESTIS ATROPHY; TOXICOKINETICS; ANATOMY AND HISTOLOGY; ANIMAL; BLOOD; CARCINOGEN TESTING; CHEMICALLY INDUCED; DRUG EFFECTS; GRANULOMA; LIVER; LUNG; ONCOGENE RAS; OVARY; PATHOLOGY; SPLEEN; TESTIS; TRANSGENIC MOUSE;

ANIMALIA; MUS;

ANIMALS; CARCINOGENICITY TESTS; CASPASE INHIBITORS; FEMALE; GENES, RAS; GRANULOMA; LIVER; LUNG; MALE; MICE, TRANSGENIC; OVARY; PENTANOIC ACIDS; SPLEEN; TESTIS;

EID: 84928320345     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2015.04.007     Document Type: Article

References (36)

1. Alden C.L., Lynn A., Bourdeau A., Morton D., Sistare F.D., Kadambi V.J., Silverman L. A critical review of the effectiveness of rodent pharmaceutical carcinogenesis testing in predicting for human risk. Vet. Pathol. 2011, 48:772-784.
2. Barreyro, F.J., Holod, S., Finocchietto, P.V., Camino, A.M., Aquino, J.B., Avagnina, A., Carreras, M.C., Poderoso, J.J., Gores, G.J., (2014). The pan-caspase inhibitor Emricasan (emricasan) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. [Epub ahead of print].
3. Birkedal C., Tapscott W.J., Giadrosich K., Spence R.K., Sperling D. Minocycline-induced black thyroid gland: medical curiosity or a marker for papillary cancer?. Curr. Surg. 2001, 58:470-471.
4. Canbay A., Feldstein A., Baskin-Bey E., Bronk S.F., Gores G.J. The caspase inhibitor emricasan attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J. Pharmacol. Exp. Ther. 2004, 308:1191-1196.
5. Camp N.J., Parry M., Knight S., Abo R., Elliott G., Rigas S.H., Balasubramanian S.P., Reed M.W., McBurney H., Latif A., Newman W.G., Cannon-Albright L.A., Evans D.G., Cox A. Fine-mapping CASP8 risk variants in breast cancer. Cancer Epidemiol. Biomark. Prev. 2012, 21:176-181.
6. Carter B.Z., Kornblau S.M., Tsao T., Wang R.Y., Schober W.D., Milella M., Sung H.G., Reed J.C., Andreeff M. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 2003, 102:4179-4186.
7. Cepelova M., Kamaradova K., Kabíckova E., Stary J., Cumlivska E., Kodet R., Gajdos P. Expression of the active caspase-3 in children and adolescents with classical Hodgkin lymphoma. Cesk. Pathol. 2014, 50:40-44.
8. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 2000, 6:797-801.
9. Chen-Deutsch X., Kutner A., Harrison J.S., Studzinski G.P. The pan-caspase inhibitor Q-VD-OPh has anti-leukemia effects and can interact with vitamin D analogs to increase HPK1 signaling in AML cells. Leuk. Res. 2012, 36:884-888.
10. Cos A.D., Der C.J. The dark side of Ras: regulation of apoptosis. Oncogene 2003, 22:8999-9006.
11. Cunha K.S., Caruso A.C., Faria P.A., Silva L.E., Fonseca E.C., Geller M., de Moura-Neto R.S., Lopes V.S. Evaluation of Bcl-2, Bcl-x and cleaved caspase-3 in malignant peripheral nerve sheath tumors and neurofibromas. An. Acad. Bras. Cienc. 2013, 85:1497-1511.
12. EU, 1997. Adopted by CPMP, issued as CPMP/ICH/299/95.
13. Gdynia G., Grund K., Eckert A., Böck B.C., Funke B., Macher-Goeppinger S., Sieber S., Herold-Mende C., Wiestler B., Wiestler O.D., Roth W. Basal caspase activity promotes migration and invasiveness in glioblastoma cells. Mol. Cancer Res. 2007, 5:1232-1240.
14. Hoglen N.C., Chen L.S., Fisher C.D., Hirakawa B.P., Groessl T., Contreras P.C. Characterization of emricasan (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. J. Pharmacol. Exp. Ther. 2004, 309:634-640.
15. Hoglen N.C., Anselmo D.M., Katori M., Kaldas M., Shen X.D., Valentino K.L., Lassman C., Busuttil R.W., Kupiec-Weglinski J.W., Farmer D.G. A caspase inhibitor, emricasan, ameliorates early hepatic injury in an ex vivo rat model of warm and cold ischemia. Liver Transpl. 2007, 13:361-366.
16. ICH, 2014. (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use), Guideline S1B "Testing for Carcinogenicity in Pharmaceuticals. Available at: (accessed 21.10.14). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S1B/Step4/S1B_Guideline.pdf.
17. Jiang B.P., Le L., Xu L.J., Xiao P.G. Minocycline inhibits ICAD degradation and the NF-κB activation induced by 6-OHDA in PC12 cells. Brain Res. 2014, 1586:1-11.
18. Kuraishy A., Karin M., Grivennikov S.I. Tumor promotion via injury- and death-induced inflammation. Immunity 2011, 2011(35):467-477.
19. Li C., Lu J., Liu Z., Wang L.E., Zhao H., El-Naggar A.K., Sturgis E.M., Wei Q. The six-nucleotide deletion/insertion variant in the CASP8 promoter region is inversely associated with risk of squamous cell carcinoma of the head and neck. Cancer Prev. Res. (Phila) 2010, 3:246-253.
20. Marino G., Niso-Santano M., Baehrecke E.H., Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2014, 15:81-94.
21. MHLW, 1998. PMSB/ELD notification No. 548.
22. Moquin D., Chan F.K. The molecular regulation of programmed necrotic cell injury. Trends Biochem. Sci. 2010, 35:434-441.
23. Morton, D., Sistare, F.D., Nambiar, P.R., Turner, O.C., Radi, Z., Bower, N., 2013. Regulatory forum commentary: alternative mouse models for future cancer risk assessment. Toxicol. Pathol. 42(5), 799-806.
24. Orrenius S., Nicotera P., Zhivotovsky B. Cell death mechanisms and their implications in toxicology. Toxicol. Sci. 2011, 119:3-19.
25. Paranjpe M.G., Elbekai R.H., Shah S.A., Hickman M., Wenk M.L., Zahalka E.A. Historical control data of spontaneous tumors in transgenic CByB6F1-Tg(HRAS)2Jic (Tg.rasH2) mice. Int. J. Toxicol. 2013, 32:48-57.
26. Peto, R., Pike, M.C., Day, N.E., Gray, R.G., Lee, P.N., Parish, S., Peto, J., Richards, S., and Wahrendorf, J., 1980. Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. In: Evaluation of the Carcinogenic Risk of Chemicals to Humans. Long and Short-term Screening Assays for Carcinogens: A critical Appraisal, Supplement 2. IARC Scientific Publications, Lyon, France, pp. 311-426.
27. Pockros P.J., Schiff E.R., Shiffman M.L., McHutchison J.G., Gish R.G., Afdhal N.H., Makhviladze M., Huyghe M., Hecht D., Oltersdorf T., Shapiro D.A. Oral emricasan, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 2007, 46:324-329.
28. Shiffman M.L., Pockros P., McHutchison J.G., Schiff E.R., Morris M., Burgess G. Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 2010, 31:969-978.
29. Suemizu, H., Ohnishi, Y., Maruyama, C., Tomisawa, M., Muguruma, K., Hioki, K., Usui, T., Kimura, M., Tamaoki, N., Nomura, T., 2000. Molecular biological studies in the rasH2 transgenic mouse. In: Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing. International Life Sciences Institute, Washington, DC.
30. Tamaoki N. The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis. Toxicol. Pathol. 2001, 29:81-89.
31. Tilly J.L., Kowalski K.I., Johnson A.L., Hsueh A.J. Endocrinology 1991, 129:2799-2801.
32. Ueno Y., Ohmi T., Yamamoto M., Kato N., Moriguchi Y., Kojima M., Shimozono R., Suzuki S., Matsuura T., Eda H. Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. J. Pharmacol. Sci. 2007, 105:201-205.
33. US FDA, 1998. Federal Register, vol. 63, p. 8983.
34. Usui T., Mutai M., Hisada S., Takoaka M., Soper K.A., McCullough B., Alden C. CB6F1-rasH2 mouse: overview of available data. Toxicol. Pathol. 2001, 29(Suppl.):90-108.
35. Vanlangenakker N., Vanden Berghe T., Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ. 2012, 19:75-86.
36. Wang X., Figueroa B.E., Stavrovskaya I.G., Zhang Y., Sirianni A.C., Zhu S., Day A.L., Kristal B.S., Friedlander R.M. Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury. Stroke 2009, 40:1877-1885.